Company Overview
Company Type: Public Company
Website: www.vbivaccines.com
Number of Employees: 193
Ticker: VBIV (NasdaqCM)
Year Founded: -


Business Description
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

Financial Information (Currency: CAD, in mm) 
Total Revenue
2.5
Market Capitalization
18.3
TEV/Total Revenue
24.9x
EBITDA
(105.9)
Total Enterprise Value
61.7
TEV/EBITDA
NM
EBIT
(108.7)
Cash & ST Invst.
28.5
P/Diluted EPS Before Extra
NM
Net Income
(162.4)
Total Debt
71.9
Price/Tang BV
NM
Capital Expenditure
(4.6)
Total Assets
120.8
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.19)
(0.77)
(7.69)
(2.60)
(2.46)
Revenue (mm)
18.12
2.13
21.88
16.41
28.19

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
2.85x

Non-Periodic Estimates

Recommendation
Outperform (2.00)
Target Price
8.21
Potential Upside
883.61%


Key Professionals
Name
Title
Baxter, Jeffery R.
President, CEO & Director
Beattie, Nell 
CFO, Head of Corporate Development & Director
Anderson, David Evander
Chief Scientific Officer
Anderson, Nicole 
Director of Corporate Communications & Investor Relations
Kartsaklis, Athena 
Senior VP of Finance, Chief Compliance Officer & Principal Financial Officer
Buckley, T. Adam
Senior Vice President of Business Development
Diaz-Mitoma, Francisco 
Chief Medical Officer
Dillman, John Robert
Chief Commercial Officer
Mazaltov, Avi 
Global Head of Manufacturing & GM of SciVac
Nossov, Misha 
Senior VP of Global Commercial Supply Strategy & Head of Europe

Key Board Members
Name
Title
Gillis, Steven S. 
Independent Chairperson of the Board
Baxter, Jeffery R.
President, CEO & Director
Beattie, Nell 
CFO, Head of Corporate Development & Director
Braga, Damian A.
Chairperson of the Commercial Advisory Board & Independent Director
Cordeiro, Joanne 
Independent Director
De Wilde, Michel 
Independent Director and Chair of Scientific & Clinical Advisory Boards
McKee, Blaine H.
Independent Director
Bresnitz, Eddy A.
Member of Commercial Advisory Board
Burger, Denis R.
Member of Scientific Advisory Board
Decker, Michael D.
Member of Commercial Advisory Board
Finn, Adam 
Member of Scientific Advisory Board
Grabenstein, John D.
Member of Commercial Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
160 Second Street Floor 3 | Cambridge, MA | 02142 | United States
Phone: 617 830 3031   

Current and Pending Investors
Arch Venture Partners, L.P., Brii Biosciences Limited (SEHK:2137), OPKO Health, Inc. (NasdaqGS:OPK), Perceptive Advisors LLC, Pontifax Venture Capital (Ran Nussbaum)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.83
Market Cap (mm)
19.1
Open
 0.81
Shares Out. (mm)
22.9
Previous Close
 0.83
Float %
85.8%
Change on Day
0.03
Shares Sold Short (mm)
0.2
Change % on Day
4.1%
Dividend Yield %
-
Day High/Low
 0.85/ 0.79
Diluted EPS Excl. Extra Items
(18.86)
52 wk High/Low
 30.78/ 0.77
P/Diluted EPS Before Extra
NM
Volume (mm)
0.09
Avg 3M Dly Vlm (mm)
0.87
Beta 5Y
1.86


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
NasdaqCM:VBIV - Common Stock


Index Membership
S&P Completion Index (CI);S&P TMI Index;S&P Completion Index (CI) Health Care (US Dollar);S&P TMI Health Care


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
VBI Vaccines Inc.
VBI Vaccines Inc., a biopharmaceutical company, engages in developing infectious disease and immuno-oncology vaccines in the United States. The company develops eVLP vaccine platform that allows for the design of enveloped (“e”) virus-like particle vaccines that closely mimic the target virus. Its lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine. The company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can preserve vaccine potency and withstand storage or shipment at fluctuating temperatures. It has subcontractor arrangements with Paragon Bioservices, Inc., collaboration and option license agreement with Sanofi, development collaboration with Columbia University’s Brain Tumor Center, and evaluation and option agreement with GlaxoSmithKline Biologicals SA. VBI Vaccines Inc. was founded in 2001 and is based in Cambridge, Massachusetts

United States and Canada
Biotechnology
0.00
8.00
2.00
Levon Resources Ltd. prior to Spin-off of Existing Business
As of July 9, 2015, Levon Resources Ltd. was acquired by VBI Vaccines, Inc., in a reverse merger transaction. Levon Resources Ltd. acquires, explorares, and develops natural resource properties in Mexico. It explores for silver, gold, zinc, lead, and copper ores. The company’s flagship project is the Cordero-Sanson project that includes approximately 37,000 hectares of contiguous mining claims located near the Hidalgo Del Parral, Chihuahua, Mexico. Levon Resources Ltd. was founded in 1965 and is headquartered in Vancouver, Canada.

United States and Canada
Silver
-
73.00
0.00
Ruf and Norma Sass Properties
Ruf and Norma Sass Properties comprise 37 unpatented gold mining claims. The assets are located in the United States.

United States and Canada
Gold
-
-
-
SciVac Hong Kong Limited
SciVac Hong Kong Limited operates as a subsidiary of VBI Vaccines Inc.   

Asia / Pacific
-
-
-
-
Scivac Ltd.
Scivac Ltd. operates as a subsidiary of VBI Vaccines Inc. 

Africa / Middle East
Biotechnology
11.00
-
-
Variation Biotechnologies (US), Inc

United States and Canada
-
-
-
-
VBI Vaccines (Delaware) Inc
VBI Vaccines (Delaware) Inc operates as a subsidiary of VBI Vaccines Inc.  

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-5-2023
-
Public Offering
Target
VBI Vaccines Inc. (NasdaqCM:VBIV)


3.00
Jul-5-2023
Jul-6-2023
Public Offering
Target
VBI Vaccines Inc. (NasdaqCM:VBIV)


18.00
Sep-14-2022
-
Private Placement
Target
VBI Vaccines Inc. (NasdaqCM:VBIV)


70.00
Aug-26-2022
-
Shelf Registration
Target
VBI Vaccines Inc. (NasdaqCM:VBIV)


300.00
Aug-26-2022
-
Public Offering
Target
VBI Vaccines Inc. (NasdaqCM:VBIV)


125.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-27-2023
Product-Related Announcements
VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901
Sep-07-2023
Product-Related Announcements
VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
Jul-19-2023
Product-Related Announcements
VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
Jul-06-2023
Follow-on Equity Offerings
VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.
Jul-05-2023
Client Announcements
Brii Biosciences Limited Enters into License Agreements with VBI Vaccines, Inc

Competitors
BioNTech SE (NasdaqGS:BNTX), Dynavax Technologies Corporation (NasdaqGS:DVAX), F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc. (NasdaqGS:GILD), Glaxosmithkline Biologicals S.A., GSK plc (LSE:GSK), Hookipa Biotech AG, Janssen Pharmaceuticals, Inc., Merck & Co., Inc. (NYSE:MRK), Mitsubishi Tanabe Pharma Corporation, Moderna, Inc. (NasdaqGS:MRNA), National Institutes of Health, Novavax, Inc. (NasdaqGS:NVAX), Pfizer Inc. (NYSE:PFE), Sanofi (ENXTPA:SAN), Takeda Pharmaceutical Company Limited (TSE:4502)

M&A Advisors
Amit, Halfon, Blake, Cassels & Graydon LLP, Cassel Salpeter & Co., LLC, Greenberg Traurig, LLP, Greenberg, Traurig, PA, Pearl Cohen Zedek Latzer Baratz LLP, Smythe LLP, Financial Service Arm


Advisors
Most Recent Auditor
EisnerAmper LLP
M&A Advisors
Amit, Halfon, Blake, Cassels & Graydon LLP, Cassel Salpeter & Co., LLC, Greenberg Traurig, LLP, Greenberg, Traurig, PA, Pearl Cohen Zedek Latzer Baratz LLP, Smythe LLP, Financial Service Arm
Public Offering Advisors
Borden Ladner Gervais LLP, EisnerAmper LLP, Haynes and Boone, LLP, National Securities Corporation, Noble International Investments Inc., Stikeman Elliott LLP


Most Recent Auditor
EisnerAmper LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:23 AM
VBIV
VBI Vaccines Inc 2023_10_05
Reports
15
ValuEngine, Inc.

Oct 02, 2023 05:46 AM
VBIV
ValuEngine Rating and Forecast Report for VBIV
Reports
11
Plunkett Research, Ltd.
Plunkett Research Team
Sep 19, 2023 05:05 AM
VBIV
VBI Vaccines Inc: Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within Its Industry
EPS Estimates*
86
Jefferson Research & Management

Sep 15, 2023 12:58 PM
VBIV
Jefferson Financial - VBI Vaccines Inc.
Reports
11
GlobalData

Sep 15, 2023 01:04 AM
VBIV
VBI Vaccines Inc (VBIV.NASD) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
114
GlobalData

Sep 12, 2023 03:42 AM
VBIV
VBI Vaccines Inc (VBIV.NASD) - Financial Analysis Review
Reports
354
Jefferson Research & Management

Sep 08, 2023 01:01 PM
VBIV
Jefferson Financial - VBI Vaccines Inc.
Reports
11
S&P Global Compustat

Sep 07, 2023 03:07 AM
VBIV
VBI Vaccines Inc 2023_09_07
Reports
15
Raymond James & Associates
Seedhouse, Steven James
Sep 06, 2023 03:15 PM
VBIV
VBIV | New Chronic HBV Data Shows Promising Durability
Reports
9
CGS-CIMB / CIMB Research
Seedhouse, Steven James
Sep 06, 2023 03:03 PM
VBIV
US : VBI Vaccines Inc. - VBIV | New Chronic HBV Data Shows Promising Durability
Reports
12


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Brii Biosciences Limited

1,818,182

7.95

1.5

Jul-10-2023


Perceptive Advisors LLC

1,381,355

6.04

1.2

Jun-30-2023


Arch Venture Partners, L.P.

1,043,292

4.56

0.9

Jul-10-2023


BlackRock, Inc.

112,145

0.49

0.1

Jun-30-2023


Cambridge Investment Research Advisors, Inc.

100,368

0.44

0.1

Jun-30-2023


Millennium Management LLC

89,205

0.39

0.1

Jun-30-2023


Geode Capital Management, LLC

67,189

0.29

0.1

Jun-30-2023


The Vanguard Group, Inc.

62,631

0.27

0.1

Jun-30-2023


General American Investors Company, Inc.

62,583

0.27

0.1

Jun-30-2023


Eaton Vance Management

43,801

0.19

0.0

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Brii Biosciences Limited
1,818,182
1,818,182
Arch Venture Partners, L.P.
1,043,292
609,091
Millennium Management LLC
89,205
88,665
Eaton Vance Management
43,801
43,744
Y-Intercept (Hong Kong) Limited
39,772
39,772

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Perceptive Advisors LLC
1,381,355
(363,143)
BlackRock, Inc.
112,145
(313,890)
State Street Global Advisors, Inc.
30,050
(100,487)
Geode Capital Management, LLC
67,189
(62,699)
Northern Trust Global Investments
15,616
(37,373)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Analytical Development Services, Contract Development Services, Formulation and Filling Services, PreHevbri, Prophylactic 3-Antigen Hepatitis B Vaccine (Future), Protein Purification Services, Sci-B-Vac, Upstream Development Process Services, VBI-1501 (Future), VBI-1901 (Future), VBI-2501 (Future), VBI-2601 (Future), VBI-2900 (Future), VBI-2901 (Future), VBI-2902 (Future), VBI-2905 (Future), VIR-2218 (Future)


Upcoming Events
Date/Time
Type
Nov-14-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-27-2023
-
VBI Vaccines Inc. (NasdaqCM:VBIV)
SEDAR
News Releases
163 KB
Sep-27-2023
-
VBI Vaccines Inc. (NasdaqCM:VBIV)
SEDAR
News Releases
115 KB
Sep-27-2023
Sep-27-2023
VBI Vaccines Inc. (NasdaqCM:VBIV)
SEC
8-K (7.01, 9.01)
234 KB
Sep-07-2023
-
VBI Vaccines Inc. (NasdaqCM:VBIV)
SEDAR
News Releases
174 KB
Sep-07-2023
-
VBI Vaccines Inc. (NasdaqCM:VBIV)
SEDAR
News Releases
130 KB
Sep-07-2023
Sep-07-2023
VBI Vaccines Inc. (NasdaqCM:VBIV)
SEC
8-K (7.01, 9.01)
265 KB
Sep-06-2023
-
VBI Vaccines Inc. (NasdaqCM:VBIV)
SEDAR
News Releases
179 KB
Sep-06-2023
Sep-06-2023
VBI Vaccines Inc. (NasdaqCM:VBIV)
SEC
8-K (7.01, 9.01)
250 KB
Sep-06-2023
-
VBI Vaccines Inc. (NasdaqCM:VBIV)
SEDAR
News Releases
110 KB
Aug-14-2023
Jun-30-2023
VBI Vaccines Inc. (NasdaqCM:VBIV)
SEDAR
Interim Financial Statements
447 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Arch Venture Partners, L.P.
Jul-10-2023
Ordinary Shares
609,090
1,374,617
Open Market Acquisition
140.28
Multiple
Arch Venture Partners, L.P.
Jul-10-2023
Ordinary Shares
609,090
1,374,617
Private Acquisition
140.28
Form 4
Arch Venture Partners, L.P.
Apr-12-2023
Ordinary Shares
(12,591,856)
0
Other Disposition
(92.35)
Multiple
-
Apr-12-2023
Ordinary Shares
(2,925,189)
0
Other Disposition
-
Exchange Announcement
-
Apr-12-2023
Ordinary Shares
(9,666,667)
0
Other Disposition
-
Exchange Announcement
Gillis M.D., Ph.D., Steven S.  (Independent Chairperson of the Board)
Apr-12-2023
Ordinary Shares
(81,602)
-
Other Disposition
(96.67)
Multiple
Perceptive Advisors LLC
Apr-04-2023 - Apr-06-2023
Ordinary Shares
(363,157)
(2,018,302)
Open Market Disposition
(20.03)
Form 4
-
Apr-04-2023
Ordinary Shares
(160,354)
(1,052,780)
Open Market Disposition
-
Form 4
-
Apr-05-2023
Ordinary Shares
(61,085)
(325,851)
Open Market Disposition
-
Form 4
-
Apr-06-2023
Ordinary Shares
(141,719)
(639,672)
Open Market Disposition
-
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Gillis, Steven S. 
Independent Chairperson of the Board
617 830 3031
-
sgillis@archventure.com
Baxter, Jeffery R.
President, CEO & Director
617 830 3031
-
jbaxter@vbivaccines.com
Beattie, Nell 
CFO, Head of Corporate Development & Director
617 830 3031
-

Braga, Damian A.
Chairperson of the Commercial Advisory Board & Independent Director
617 830 3031
-

Cordeiro, Joanne 
Independent Director
617 830 3031
-

De Wilde, Michel 
Independent Director and Chair of Scientific & Clinical Advisory Boards
617 830 3031
-

McKee, Blaine H.
Independent Director
617 830 3031
-

Bresnitz, Eddy A.
Member of Commercial Advisory Board
617 830 3031
-

Burger, Denis R.
Member of Scientific Advisory Board
1-800-325-3424
-

Decker, Michael D.
Member of Commercial Advisory Board
617 830 3031
-

Finn, Adam 
Member of Scientific Advisory Board
617 830 3031
-
-
Grabenstein, John D.
Member of Commercial Advisory Board
617 830 3031
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Baxter, Jeffery R.
President, CEO & Director
617 830 3031
-
jbaxter@vbivaccines.com
Beattie, Nell 
CFO, Head of Corporate Development & Director
617 830 3031
-

Anderson, David Evander
Chief Scientific Officer
617 830 3031
-

Anderson, Nicole 
Director of Corporate Communications & Investor Relations
(617) 830-3031x124
-

Kartsaklis, Athena 
Senior VP of Finance, Chief Compliance Officer & Principal Financial Officer
617 830 3031
-

Buckley, T. Adam
Senior Vice President of Business Development
617 830 3031
-

Diaz-Mitoma, Francisco 
Chief Medical Officer
617 830 3031
-

Dillman, John Robert
Chief Commercial Officer
617 830 3031
-

Mazaltov, Avi 
Global Head of Manufacturing & GM of SciVac
617 830 3031
-

Nossov, Misha 
Senior VP of Global Commercial Supply Strategy & Head of Europe
617 830 3031
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
